GlobeNewsWire
21 Aug 2026, 11:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Arbutus Biopharma intends to repurchase up to US$230 million of its common shares through a modified Dutch Auction tender offer. — A significant share repurchase program reduces float and returns capital to shareholders, typically creating strong upward price pressure.
+0.80The company has set a purchase price range for the tender offer between US$5.00 and US$5.75 per share. — Providing a concrete price floor/ceiling gives the market a valuation benchmark and immediate target for the stock price.
+0.60Arbutus is continuing to pursue legal action against Pfizer and BioNTech for infringement of its lipid nanoparticle (LNP) technology. — Ongoing litigation represents a potential source of significant future cash inflows, though the outcome remains uncertain.
+0.40Continue reading
6 related stories
Search tags
The share repurchase will be funded entirely through the company's existing cash on hand, stemming from a settlement with Moderna. — Confirms the buyback is not dependent on new debt, though it reduces the company's cash reserves for R&D or operations.
+0.20Which stocks this story touches
The company is initiating a $230 million share repurchase following a successful legal settlement with Moderna.
The company is explicitly named as an infringer of Arbutus' patents and is facing ongoing legal enforcement.
The company is explicitly named as an infringer of Arbutus' patents and is facing ongoing legal enforcement.
The company entered into a settlement payment to Arbutus, acknowledging the validity of Arbutus' LNP technology.
The company is serving as the Dealer-Manager for the share repurchase offer.
[mutual] Arbutus and Moderna reached a legal settlement in March 2026 regarding lipid nanoparticle technology.
[mutual] Arbutus is vigorously enforcing intellectual property rights against Pfizer for use of its patented LNP technology.
[mutual] Arbutus is vigorously enforcing intellectual property rights against BioNTech for use of its patented LNP technology.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
24/7 Wall Street
1d ago
